Equities researchers at Ascendiant Capital Markets assumed coverage on shares of Aastrom Biosciences (NASDAQ: ASTM) in a report issued on Tuesday. The firm set a “strong-buy” rating and a $4.25 price target on the stock.
Shares of Aastrom Biosciences traded up 1.30% during mid-day trading on Tuesday, hitting $2.3501. Aastrom Biosciences has a one year low of $1.75 and a one year high of $3.47. The company’s market cap is $91.0 million.
ASTM has been the subject of a number of other recent research reports. Analysts at Oppenheimer (NYSE: OPY) reiterated a “market perform” rating on shares of Aastrom Biosciences in a research note to investors on Friday, May 11st. Analysts at WBB Securities upgraded shares of Aastrom Biosciences from a “hold” rating to a “speculative buy” rating in a research note to investors on Monday, April 16th. They now have a $3.00 price target on the stock, up previously from $2.50.
Aastrom Biosciences, Inc. (Aastrom) is in the development-stage. Aastrom is a regenerative medicine company focused on the development of cell therapies to repair or regenerate damaged or diseased tissues.